SCHEMBL931685

SCHEMBL931685

CCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCCN)OCCCCCCCCCCCCCCCC

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 1/20 0.73
LPAR1 Q92633 9/20 0.70
LPAR3 Q9UBY5 9/20 0.70
LPAR2 Q9HBW0 6/20 0.62
PLA2G2D Q9UNK4 1/20 0.54
TLR2 O60603 3/20 0.51
LPAR5 Q9H1C0 6/20 0.49
LPAR6 P43657 5/20 0.49
LPAR4 Q99677 5/20 0.49
P2RY10 O00398 2/20 0.48
AKT1 P31749 2/20 0.46
PLCG2 P16885 1/20 0.46
PIK3R1 P27986 1/20 0.46
AKT2 P31751 1/20 0.46
PIK3CA P42336 1/20 0.46
AKT3 Q9Y243 1/20 0.46
GAB1 Q13480 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29133994 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL28622692 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL29206151 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL28622690 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL23300849 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL2702607 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL25394384 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL21568785 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL22092476 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL29692534 1.00 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293443-A1 HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE GORDTS PHILIP L S M (US) 2024-09-05 US claimed
CN-112469826-B Magnetic-based biopanning method by attachment of magnetic beads to cells (株)爱恩德生物 2024-02-09 CN claimed
CN-117157104-A Targeting multiple T cell types using spherical nucleic acid vaccine architecture 西北大学 2023-12-01 CN claimed
CN-112469826-A Magnetic based biopanning method by magnetic bead attachment to cells (株)爱恩德生物 2021-03-09 CN claimed
US-9164108-B2 Liposome-based microarray and methods of use thereof SRI INTERNATIONAL (US) 2015-10-20 US claimed
EP-2680004-A2 Compositions and methods for detecting cancer The Regents of the University of California (US) 2014-01-01 EP claimed
US-20110177614-A1 COMPOSITIONS AND METHODS FOR DETECTING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-07-21 US claimed
EP-4694867-A2 LIPID NANOPARTICLES FOR DELIVERY OF AGENTS Massachusetts Institute of Technology (US) 2026-02-18 EP disclosed
US-12508226-B2 Lipid composition FUJIFILM CORPORATION (JP) 2025-12-30 US disclosed
US-20250320280-A1 BROADLY NEUTRALIZING ANTIBODIES THAT TARGET HIV ENV V3 N-GLYCANS UNIV ROCKEFELLER (US) 2025-10-16 US disclosed
EP-4328309-B1 LIPID COMPOSITION FUJIFILM CORP (JP) 2025-07-02 EP disclosed
US-12338277-B2 Broadly neutralizing antibodies that target HIV ENV V3 N-glycans THE ROCKEFELLER UNIVERSITY (US) 2025-06-24 US disclosed
US-20250049713-A1 LIPID NANOPARTICLES FOR DELIVERY OF AGENTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2025-02-13 US disclosed
US-20120184461-A1 PRINTING OF FSL CONSTRUCTS BOVIN NICOLAI VLADIMIROVICH (RU) 2012-07-19 US disclosed
EP-2449386-A1 PRINTING OF FSL CONSTRUCTS Bovin, Nikolai Vladimirovich (RU) 2012-05-09 EP disclosed
US-20110177614-A1 COMPOSITIONS AND METHODS FOR DETECTING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-07-21 US disclosed
US-7906147-B2 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography NANOPROBES, INC. (US) 2011-03-15 US disclosed
WO-2011002310-A1 PRINTING OF FSL CONSTRUCTS BOVIN NICOLAI VLADIMIROVICH (RU) 2011-01-06 WO disclosed
US-20080089836-A1 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography NANOPROBES, INC. (US) 2008-04-17 US disclosed
US-20040259142-A1 Products and methods IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293443-A1 HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE FABP4, APMAP, SLC2A4 PLA2G2C 1147/4885LPAR1 2087/4885LPAR3 2020/4885
US-20250049713-A1 LIPID NANOPARTICLES FOR DELIVERY OF AGENTS FABP3, LIPC, PHOSPHO1 PLA2G2C 285/4885LPAR1 32/4885LPAR3 20/4885
US-20080089836-A1 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography TFRC, FABP1, SCARB1 PLA2G2C 2431/4885LPAR1 232/4885LPAR3 322/4885
US-12508226-B2 Lipid composition APOB, NAF1, SLC27A1 PLA2G2C 559/4885LPAR1 7/4885LPAR3 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.